Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Large cap

Pfizer Q2 profit up 6.6% to ₹204 cr, CFO gap lingers

Revenue rose 8.3% to ₹653 cr, with no exceptional charges lifting net profit. But the board meeting came a day after the CFO resigned, leaving a leadership hole.

1 earlier story on Pfizer Ltd.
Mkt cap₹20,407 cr
P/E28.25×
ROE18.20%
Debt / eq.0.00
Div yld1.66%
₹204.47 cr Net profit for the June quarter, up 6.6% year-on-year

What's new

  • Revenue of ₹653 cr, up 8.3% YoY.
  • Net profit of ₹204 cr, up 6.6% YoY.
  • No exceptional items this quarter versus ₹49 cr last year.
  • Results approved a day after CFO Amit Agarwal resigned.

Why this matters

Pfizer delivered a clean quarter with steady growth and a debt-free balance sheet. But the sudden CFO exit with no successor named shifts attention to transition risk. The open question is who manages the next quarter's numbers.

What we're watching

  • Timeline for a new CFO appointment.
  • Whether operating margins stay above 39% in coming quarters.
  • Any impact from the end of the Cipla brand distribution exceptional.

The full read

Pfizer's June quarter is a picture of steady execution. Revenue climbed 8.3% to ₹653.17 crore, net profit rose 6.6% to ₹204.47 crore, and for the first time in two years there were no exceptional items weighing on the bottom line. Operating margins held at ~39.6% — healthy by any measure. The balance sheet remains debt-free with ample cash. But the quarter's real news came a day before the earnings: CFO Amit Agarwal resigned, and no replacement is in place yet. For a company that relies on stable financial stewardship, the leadership gap is the one number the P&L doesn't capture. The growth is real, but the open question is who manages the next quarter's numbers.

Questions answered

How did Pfizer's revenue and profit perform in Q2?
Revenue was ₹653.17 crore, up 8.3% year-on-year. Net profit was ₹204.47 crore, up 6.6% from ₹191.75 crore a year earlier.
Why were there no exceptional items this quarter?
The prior year had exceptional charges of ₹49.16 crore related to the Cipla brand distribution deal and labour code provisions. Those costs did not recur in Q2.
What is the status of the CFO position?
CFO Amit Agarwal resigned on July 27, 2026, a day before the board approved the Q2 results. No successor has been named.
What are Pfizer's operating margins?
Operating margins for the quarter were around 39.6%, reflecting steady profitability.
Is Pfizer carrying any debt?
No. The company has a debt-free balance sheet and strong cash position, supporting dividends and operations.
Mentioned: ₹653.17 cr revenue · ₹204.47 cr net profit · CFO resignation
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Pfizer Ltd.

Pharmaceuticals
₹21,456 cr
P/E 29.70×

Latest quarter · Mar 2026

Sales₹629 cr
Net profit₹200 cr
Op. margin+37.5%
EPS₹43.68

Strength & growth

Debt / equity0.00×
Current ratio6.06×
Sales CAGR+2.2%
EPS CAGR+8.7%
Financials via Tijori — a research aid, not investment advice.PFIZER on Tijori
  1. 28 Jul 2026 · 1:57 PM IST Pfizer Q2 profit up 6.6% to ₹204 cr, CFO gap lingers
  2. 1d ago Pfizer loses CFO Amit Agarwal; no successor named